Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.

In our cohort the clinical response in the induction phase was similar to those of registered trials, despite surprising better results for CD. During the maintenance phase we observed an higher drop out than in the reported literatures. Of note, its good safety profile makes vedolizumab a reliable choice in patients with contraindications to anti-tumor necrosis factor agents.